CA-JUNIPER-NETWORKS
22.2.2024 12:01:30 CET | Business Wire | Press release
Juniper Networks (NYSE: JNPR), a leader in secure, AI-Native Networks, today announced that it is providing KK Networks, one of the fastest growing internet Service Providers (ISPs) in Pakistan, with a scalable and resilient Cloud Metro network. The network will provide residential users with affordable internet access and an enhanced quality of experience, while also providing a sustainable services delivery platform for KK Networks (KKN). KKN is also expanding its offering with business-grade internet services using the transformed network. The new, robust Cloud Metro infrastructure will cover extensive areas of Lahore, Pakistan with plans to extend further over time.
The company has also upgraded its data centers with state-of-the-art automation software and secure, high-performance platforms from Juniper to streamline and optimize the design, deployment and operations of the network fabric. This will complement the Cloud Metro platform, further enhancing the overall user experience at scale.
KKN is a fast-growing internet service provider that has rapidly evolved to accommodate the surging demand in Pakistan for digital services. Following a four-fold increase in its user base in Lahore in just two years, KKN needed a robust metro network to handle the increasing demand on bandwidth which today serves 140,000 residential customers and growing. Juniper’s Cloud Metro solution was chosen specifically to provide a platform that can scale alongside KKN’s continued traffic growth and support the distributed nature of its user base and therefore traffic patterns.
With its previous network, internet performance would often slow during peak hours. Frequent network congestion meant that subscribers’ internet connections would often drop. With a transformed metro network that keeps up with the pace and scale of demand, KKN can now deliver reliable internet connectivity with enhanced quality of experience for its subscribers. The company is continuing a high-growth trajectory with an opportunity to bring high-performance, differentiated internet services to thousands of homes and businesses in Pakistan.
KKN has an ongoing objective to help support and enhance the digital economy in Pakistan. Approximately half of the 230 million population is still without access to broadband internet services today, according to the Pakistan Telecom Authority. The Cloud Metro network from Juniper equips KKN to create reliable, high-quality digital connections that can improve economic opportunity, build a stronger community and foster better education. Juniper Cloud Metro’s compact and efficient system design enables KKN to deliver more energy-efficient operations. Additional to improving its own operational costs, this also bolsters its ability to offer affordable broadband for customers across the region.
News Highlights
- KKN deployed the Juniper Cloud Metro solution to scale capacity, improve resiliency and deliver low-latency user experiences for residential and business services.
- High-capacity Juniper ACX7100-32C Cloud Metro routers form the aggregation network, meeting KKN’s growth requirements with a compact, power-efficient design for operational efficiency.
- The Juniper ACX710 Universal Metro Router is used for the access layer. As a compact, hardened platform, the ACX710 can be deployed indoors or outdoors. Its high port density and small footprint allow KKN to support a higher number of customers efficiently. Lower energy consumption means KKN can deliver its services more sustainably.
- KKN also uses Juniper’s AI-driven, high-performance EX2300 Ethernet Switch to extend connectivity to its business customers. The cloud-ready EX switches are easy to onboard, configure and manage, ensuring quick and easy deployment for KKN’s business customers.
- KKN uses Juniper QFX5120 switches for the data center underlay network, EVPN-VXLAN for the overlay network and EX2300s to create a data center fabric that supports up to 100GbE interfaces. This enables the network to keep pace with customer demand for content delivery, voice, video and other bandwidth-hungry services.
- KKN plans to deploy Juniper Apstra™ intent-based networking software in its product roadmap, to automate and validate the design, deployment and operation of the data center fabric to ensure reliable operations. With multi-vendor support, Apstra will empower KKN to automate and manage networks across any data center location, vendor and topology.
Supporting Quotes
“KKN is determined to improve and expand internet services across Lahore, Pakistan, to ensure that our customers have the best digital experiences. With Juniper, our new Cloud Metro network has observed 99.9 per cent uptime, delivering an accessible, high-performance digital platform to 14 regions in Lahore. With this new low-latency, resilient network, KKN can continue to grow our customer base with confidence that residential and business customers can rely on great connectivity to a sustainable network that can handle the demand.”
- Imran Ali, CEO, KK Networks
“Juniper continuously strives to enable remarkable digital experiences for our customers’ users, and the Cloud Metro solution is a perfect example of our market-leading innovation, applying cloud principles to metro networks. KK Networks is undertaking a transformative journey, upgrading from a traditional “Retro Metro” that cannot keep up with demand for today’s digital services at scale, to Juniper’s high-performance Cloud Metro infrastructure that makes sustainable, future-proof business growth possible for service providers globally.”
- AE Natarajan, Executive Vice President, Juniper Networks
Additional Resources
Juniper Solution: Cloud Metro
About Juniper Networks
Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up across the AIOps layer and our systems to fully harness the power of AI. From real-time fault isolation to proactive anomaly detection and self-driving corrective actions, it provides campus, branch, data center, and WAN operations with next-level predictability, reliability, and security. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222111099/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
